FIELD: medicine.SUBSTANCE: group of inventions refers to medicine. A method of reducing A? A? deposition neurotoxicity and microglyosis in an animal or a human suffering a cerebral amyloidogenic disease involving administering a therapeutically effective amount of enantiomer-rich (-)-nilvadipine into the animal or human. The further methods represent methods of reducing a risk of A? A? deposition neurotoxicity and microglyosis in the animal or human suffering the traumatic cerebral affection by ...

ABSTRACT - 596395 The disclosure relates to a solid preparation comprising (i) compound selected from the group consisting of 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid and 2-ethoxy-1-[[2'-(45-dihydro-5-oxo-124-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid or a salt thereof (ii) a sugar alcohol selected from...

A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine anipamil barnidipine benidipine bepridil darodipine diltiazem efonidipine felodipine isradipine lacidipine lercanidipine lidoflazine manidipine mepirodipine nicardipine...

A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipi...

Disclosed is a pharmaceutical composition comprising optically active nilvadipine and a pharmaceutically acceptable carrier the pharmaceutical composition comprising an excess of (-)-nilvadipine relative to (+)-nilvadipine wherein the pharmaceutical composition is in a form suitable for parenteral oral or interperitoneal administration. Also disclosed is The use of a therapeutically effective amount of enantiomerically-enriched (-)-nilvadipine in the manufacture of a composition for reducing the...

The present invention provides methods for reducing A&bgr; deposition A&bgr; neurotoxicity and microgliosis in an animal or human afflicted with a cerebral amyloidogenic disease such as Alzheimer's disease (AD) by administering therapeutically effective amounts of the (R)-enantiomer of the dihydropyridine compound nilvadipine also known as (−)-nilvadipine to the animal or human. Further provided are methods for reducing the risk of A&bgr; deposition A&bgr; neurotoxicity and microgliosis in...